These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34981051)

  • 1. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Chen KY; Krischuns T; Ortega Varga L; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Courtney D; O'Brien A; Baker SC; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N
    bioRxiv; 2021 Dec; ():. PubMed ID: 34981051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Chen KY; Krischuns T; Varga LO; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Delpal A; Courtney D; O'Brien A; Baker SC; Decroly E; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N
    Antiviral Res; 2022 May; 201():105272. PubMed ID: 35278581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity.
    Vlachou A; Nchioua R; Regensburger K; Kirchhoff F; Kmiec D
    Sci Rep; 2024 Sep; 14(1):20697. PubMed ID: 39237598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease.
    Milligan JC; Zeisner TU; Papageorgiou G; Joshi D; Soudy C; Ulferts R; Wu M; Lim CT; Tan KW; Weissmann F; Canal B; Fujisawa R; Deegan T; Nagaraj H; Bineva-Todd G; Basier C; Curran JF; Howell M; Beale R; Labib K; O'Reilly N; Diffley JFX
    Biochem J; 2021 Jul; 478(13):2499-2515. PubMed ID: 34198327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
    Rothan HA; Teoh TC
    Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity.
    Stobart CC; Sexton NR; Munjal H; Lu X; Molland KL; Tomar S; Mesecar AD; Denison MR
    J Virol; 2013 Dec; 87(23):12611-8. PubMed ID: 24027335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor.
    O'Brien A; Chen DY; Hackbart M; Close BJ; O'Brien TE; Saeed M; Baker SC
    Virology; 2021 Apr; 556():73-78. PubMed ID: 33548599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic cleavage and inactivation of the TRMT1 tRNA modification enzyme by SARS-CoV-2 main protease.
    Zhang K; Eldin P; Ciesla JH; Briant L; Lentini JM; Ramos J; Cobb J; Munger J; Fu D
    Elife; 2024 May; 12():. PubMed ID: 38814682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.
    Liu Y; Qin C; Rao Y; Ngo C; Feng JJ; Zhao J; Zhang S; Wang TY; Carriere J; Savas AC; Zarinfar M; Rice S; Yang H; Yuan W; Camarero JA; Yu J; Chen XS; Zhang C; Feng P
    mBio; 2021 Oct; 12(5):e0233521. PubMed ID: 34544279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
    Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
    Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRET-Based Self-Cleaving Biosensors for SARS-CoV-2 3CLpro Inhibitor Discovery.
    Hou N; Peng C; Zhang L; Zhu Y; Hu Q
    Microbiol Spectr; 2022 Aug; 10(4):e0255921. PubMed ID: 35758897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
    Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
    J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
    J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition.
    Heilmann E; Costacurta F; Geley S; Mogadashi SA; Volland A; Rupp B; Harris RS; von Laer D
    Commun Biol; 2022 Apr; 5(1):391. PubMed ID: 35478219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
    Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
    Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
    [No Abstract]   [Full Text] [Related]  

  • 20. A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells.
    Desmarets L; Callens N; Hoffmann E; Danneels A; Lavie M; Couturier C; Dubuisson J; Belouzard S; Rouillé Y
    Front Microbiol; 2022; 13():1031204. PubMed ID: 36246297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.